UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000004527
Receipt number R000005394
Scientific Title Randomized, double blind, crossover clinical study to evaluate the sedative effect after the treatment of 1 mg dose of ketotifen, or 10 or 20 mg dose of cetirizine using saccadic eye movement analysis in healthy male volunteers
Date of disclosure of the study information 2010/11/09
Last modified on 2010/12/27 11:24:57

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Randomized, double blind, crossover clinical study to evaluate the sedative effect after the treatment of 1 mg dose of ketotifen, or 10 or 20 mg dose of cetirizine using saccadic eye movement analysis in healthy male volunteers

Acronym

Evaluation of the sedative effect by ketotifen or cetirizine treatment using saccadic eye movement analysis

Scientific Title

Randomized, double blind, crossover clinical study to evaluate the sedative effect after the treatment of 1 mg dose of ketotifen, or 10 or 20 mg dose of cetirizine using saccadic eye movement analysis in healthy male volunteers

Scientific Title:Acronym

Evaluation of the sedative effect by ketotifen or cetirizine treatment using saccadic eye movement analysis

Region

Japan


Condition

Condition

allergic rhinitis, pollen allergy

Classification by specialty

Clinical immunology Oto-rhino-laryngology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is to evaluate the sedative effect of ketotifen (1mg) and cetirizine (10 or 20mg) by measuring saccadic peak velocity (SPV) as primary outcome using saccadic eye movement analysis. Based on the SPV's results, we subsequently analyzed the correlationship between the SPV and the published histamine H1 receptor occupancy in the brain.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Saccadic peak velocity

Key secondary outcomes

Latency
Inaccuracy
Visual Analogue Scale


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Historical

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment

No need to know


Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Single dose of Ketotifen (1 mg) by oral route

Interventions/Control_2

Single dose of Cetirizine (10 mg) by oral route

Interventions/Control_3

Single dose of Cetirizine (20 mg) by oral route

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

35 years-old >=

Gender

Male

Key inclusion criteria

Healthy volunteers enrolled this study must be agreement with the following criteria:
1.Age between 20 and 35
2.Male
3.Subjects are competent to consent, keep the rule of this study and are able to report self condition
4.Subjects who are judged eligible by the investigator in several series of medical check

Key exclusion criteria

1.Subjects who have inappropriate medical history (ex., drug abuse, alcoholism, any kind of heart, liver, kidney, lung, eye and blood diseases etc.) or who are ingested medicine during this study.
2.Smoker.
3.Any drug allergy.
4.Subjects who are using excessive alcohol regularly (cannot keep abstinence for study period)
5.Nocturnal habits during night.
6.Participation in any clinical trial within the last 3 months.
7.Subjects who are inadequate for enrollment judged by the investigators.

Target sample size

6


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Toshinori YAMAMOTO

Organization

School of Pharmacy, Showa University

Division name

Department of Clinical Pharmacy

Zip code


Address

1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555

TEL

03-3784-8221

Email



Public contact

Name of contact person

1st name
Middle name
Last name Noriko KOHYAMA

Organization

School of Pharmacy, Showa University

Division name

Department of Clinical Pharmacy

Zip code


Address


TEL


Homepage URL


Email

noriko-kyb@pharm.showa-u.ac.jp


Sponsor or person

Institute

Department of Clinical Pharmacy, School of Pharmacy, Showa University

Institute

Department

Personal name



Funding Source

Organization

Department of Clinical Pharmacy, School of Pharmacy, Showa University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Second Department of Pharmacology, School of Medicine, Showa University
Tokyo Heart Center, Dept of Clinical Pharmacology Laboratory

Name of secondary funder(s)

Showa University Research Grant for Young Researchers


IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人社団冠心会大崎病院東京ハートセンター臨床薬理研究所(東京都)


Other administrative information

Date of disclosure of the study information

2010 Year 11 Month 09 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2010 Year 10 Month 27 Day

Date of IRB


Anticipated trial start date

2010 Year 11 Month 01 Day

Last follow-up date

2010 Year 11 Month 01 Day

Date of closure to data entry

2010 Year 12 Month 01 Day

Date trial data considered complete

2010 Year 12 Month 01 Day

Date analysis concluded

2010 Year 12 Month 01 Day


Other

Other related information



Management information

Registered date

2010 Year 11 Month 09 Day

Last modified on

2010 Year 12 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005394


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name